France-headquartered May Health has secured a European CE mark for its Anavi system to address infertility in women with polycystic ovary syndrome (PCOS).

The system is positioned as a one-time treatment for women with PCOS-related infertility who have not responded to or declined first-line medications. Anavi uses targeted radiofrequency (RF) energy to ablate a small fraction of ovarian tissue with the aim of re-initiating ovulatory cycles in those with PCOS.

Women with PCOS-related infertility often struggle to become pregnant because they are unable to ovulate consistently or at all. Estimated to impact between 10% and 13% of the global population, the lack of ovulation in individuals with PCOS is linked to dysregulation of androgen production and other hormonal signals within the ovary.